基于MicroRNA-122的肝脏疾病治疗方法可能是一把双刃剑  

MicroRNA-122-based therapeutics might be a doubleedged sword to liver diseases

作　　者：程继文[1] 陈妍珂[2] 王万里[1] 李慕行[1] 吕毅[1] 

机构地区：[1]西安交通大学第一附属医院肝胆外科,陕西西安710061 [2]西安交通大学医学院,陕西西安710061

出　　处：《医学争鸣》2014年第6期26-29,共4页Negative

摘　　要：目前大量研究表明MicroRNA-122(miR-122)可能作为治疗肝脏相关疾病的有效靶点,尤其是对脂质紊乱、HCV和HCC的治疗。用miR-122的反义寡氨酸屏蔽miR-122可以降低肝和血液里的胆固醇、高密度脂蛋白、低密度脂蛋白以及甘油三酯水平,还可以抑制HCV RNA的复制;而恢复和升高miR-122的表达可以抑制HBV RNA的复制和肿瘤的生长及转移,还可以增加HCC细胞对化疗药物的敏感性。值得注意的是miR-122功能不足又可能导致肝细胞的脂肪变性和纤维化。但鉴于miR-122在多种肝脏疾病中发挥着"相反"的作用,我们认为通过改变miR-122的表达治疗肝脏疾病有可能是一把双刃剑。A lot of evidence has shown that microRNA-122 （miR-122） may be as an effective target in the treatment of liver-involved diseases, especially dyslipidemia, HCV, and HCC. MiR-122 sequestration by its antagomir leads to decreased cholesterol levels, low density lipoprotein （LDL） and high density lipoprotein （HDL） fractions, and triglyceride content in the both liver and blood. In addition, miR-122 silencing or the functional inhibition of miR-122 by anti-miR- 122 oligonucleotides causes potent and sustained inhibition of HCV replication. On the contrary, over-expression and restoration of miR-122 can stimulate the replication of HCV, but may inhibit the replication of HBV and the growth and metastasis of HCC, also sensitize HCC ceils to chemotherapeutic agents. It＇s worthy to note that miR-122 deficiency may result in steatohepatitis and liver fibrosis. Therefore, miR-122-based therapeutics might be a double-edged sword to the liver diseases due to its contradictory roles in different liver diseases.

关 键 词：MI R-122 治疗 脂质紊乱 HCV HCC 

分 类 号：R459.9[医药卫生—治疗学] R-1[医药卫生—临床医学]